Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Ascendis Pharma ADR
(NQ:
ASND
)
138.84
-0.66 (-0.47%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ascendis Pharma ADR
< Previous
1
2
3
4
5
6
Next >
Expert Ratings for Ascendis Pharma
September 22, 2022
Within the last quarter, Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings:
Via
Benzinga
Ascendis Seeks FDA Nod For TransCon PTH In Adults With Hypoparathyroidism
August 31, 2022
Ascendis Pharma (NASDAQ: ASND) has submitted a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for TransCon PTH, an investigational pro-drug designed to restore parathyroid...
Via
Benzinga
Expert Ratings for Ascendis Pharma
August 30, 2022
Analysts have provided the following ratings for Ascendis Pharma (NASDAQ:ASND) within the last quarter:
Via
Benzinga
Oppenheimer Maintains Outperform Rating for Ascendis Pharma: Here's What You Need To Know
August 11, 2022
Oppenheimer has decided to maintain its Outperform rating of Ascendis Pharma (NASDAQ:ASND) and lower its price target from $154.00 to $144.00. Shares of Ascendis Pharma are trading up 8.7% over the...
Via
Benzinga
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
August 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
What 14 Analyst Ratings Have To Say About Ascendis Pharma
May 12, 2022
Within the last quarter, Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings:
Via
Benzinga
Where Ascendis Pharma Stands With Analysts
January 27, 2022
Over the past 3 months, 4 analysts have published their opinion on Ascendis Pharma (NASDAQ:ASND) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...
Via
Benzinga
Ascendis Slammed After Growth Hormone Drug Faces An Unexpected Challenge
May 12, 2022
Ascendis Pharma sells a treatment for children with insufficient growth hormone.
Via
Investor's Business Daily
The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL
March 24, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
BofA Upgrades Ascendis Pharma After Promising TCP Phase 3 Data
March 15, 2022
Following Ascendis Pharma’s (NASDAQ: ASND) reporting of positive topline Phase III data for its PaTHway trial of TransCon PTH (TCP) in adults with hypoparathyroidism, the...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2022
March 15, 2022
Upgrades For Turquoise Hill Resources Ltd (NYSE:TRQ), BMO Capital upgraded the previous rating of Underperform to Market Perform. Turquoise Hill Resources earned $0.78 in the...
Via
Benzinga
Where Ascendis Pharma Stands With Analysts
January 06, 2022
Analysts have provided the following ratings for Ascendis Pharma (NASDAQ:ASND
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
March 14, 2022
Gainers Erytech Pharma (NASDAQ:ERYP) stock rose 18.7% to $1.65 during Monday's pre-market session. The market value of their outstanding shares is at $51.1 million....
Via
Benzinga
10 Biggest Price Target Changes For Monday
March 14, 2022
Wells Fargo raised the price target on Laredo Petroleum, Inc. (NYSE: LPI) from $72 to $113. Laredo Petroleum shares fell 2.8% to $71.00 in pre-market trading.
Via
Benzinga
Ascendis Pharma's Hypoparathyroidism Trial Meets Primary, Secondary Endpoints
March 14, 2022
Ascendis Pharma A/S (NASDAQ: ASND) announced topline data from its Phase 3 PaTHway Trial of TransCon PTH in adults with hypoparathyroidism (HP), a condition in...
Via
Benzinga
7 Biotech Stocks With Key Catalysts in March
March 09, 2022
These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways.
Via
InvestorPlace
Analyst Ratings For Ascendis Pharma
November 11, 2021
Analysts have provided the following ratings for Ascendis Pharma (NASDAQ:ASND
Via
Benzinga
Expert Ratings For Ascendis Pharma
March 07, 2022
Within the last quarter, Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...
Via
Benzinga
The Daily Biotech Pulse: NuCana Shelves Biliary Tract Cancer Study, Tricida Data Readout Pushed Back Due to Ukrainian Crisis, Synlogic Names New CFO
March 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus NuCana Discontinues Biliary Tract Cancer Study Following Futility Analysis...
Via
Benzinga
Pfizer Dives After FDA Rejects Its OPKO-Partnered Rare Disease Treatment
January 24, 2022
Pfizer stock tumbled after the FDA rejected an OPKO-partnered drug.
Via
Investor's Business Daily
Ascendis Pharma's Growth Hormone Deficiency Med Scores European Approval
January 13, 2022
The European Commission (EC) has granted marketing authorization to Ascendis Pharma A/S's (NASDAQ: ASND) Lonapegsomatropin (developed under the name TransCon hGH)....
Via
Benzinga
The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial
November 19, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Connect Biopharma Atopic Dermatitis Treatment Aces Mid-stage Study But Lack...
Via
Benzinga
Earnings Scheduled For March 2, 2022
March 02, 2022
Companies Reporting Before The Bell • SIGNA Sports United (NYSE:SSU) is expected to report quarterly loss at $0.04 per share on revenue of $283.61 million. •...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022
March 01, 2022
Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,...
Via
Benzinga
Ascendis' Hypoparathyroidism Candidate Shows Durable Benefit At 84 Weeks
November 19, 2021
Ascendis Pharma A/S (NASDAQ: ASND) announced topline results from Week 84 of its Phase 2 PaTH Forward Trial of its TransCon PTH candidate hypoparathyroidism (HP)....
Via
Benzinga
10 Biggest Price Target Changes For Monday
November 15, 2021
Keybanc boosted the price target on Netflix, Inc. (NASDAQ: NFLX) from $690 to $725. Netflix shares rose 0.2% to $683.90 in pre-market trading. Piper Sandler raised the price...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 14, 2022
February 14, 2022
Upgrades According to Mizuho, the prior rating for Murphy Oil Corp (NYSE:MUR) was changed from Neutral to Buy. In the fourth quarter, Murphy Oil showed an EPS of $0.40,...
Via
Benzinga
Ascendis Pharma A/S (ASND) Q3 2021 Earnings Call Transcript
November 10, 2021
ASND earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2022
January 06, 2022
Upgrades For Canada Goose Holdings Inc (NYSE:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021
December 08, 2021
Upgrades According to Deutsche Bank, the prior rating for Goodyear Tire & Rubber Co (NASD...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.